LH Capital


Combining Purpose With Profit

LH Capital, through its affiliates, encompasses a multi-asset class investment portfolio across all asset classes and stages. Aligned with Lyda’s values and mission, LH Capital harnesses an entrepreneurial spirit and takes investment risks in pursuit of impact, while seeking market-rate returns.

Select Portfolio Examples

Our Portfolio Spans
Asset Classes

Real Estate

Pegasus Park

In 2019, we invested in the 26-acre multi-use campus known as Pegasus Park, and worked with partners at J.Small Investments and Montgomery Street Partners to transform the property into a hub for life sciences and one of the largest social impact campuses in the country.

Venture Capital


We invested in a Flagship Pioneering fund focused on incubating and funding early-stage biotechnology companies. One of the portfolio companies of the fund is Moderna, thus we became an early investor in Moderna, which develops novel mRNA platforms and products such as their widely used vaccine for COVID-19.

Direct Investment

Reata Pharmaceuticals

Reata was incubated in 2002 at UT Southwestern Medical Center in Dallas to develop therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. In 2003, we invested in Reata, which was acquired by Biogen for $7.3 billion in 2023.



In 2022, we provided a loan to Rocky Mountain Institute to fund MiQ, a spin out non-profit created to monitor and reduce methane emissions in the oil and gas sector by establishing a certification standard for methane emissions throughout the natural gas value chain. The investment is ongoing and in its early stages.

Venture Capital

Remeditex Ventures

In 2011, Lyda Hill launched a $200 million biotechnology venture fund, Remeditex Ventures. The fund invested in promising early-stage life science technologies spinning out of Texas medical institutions. The deal sizes ranged from $50,000 to $5,000,000 across biomedical, pharmaceuticals, diagnostics, and medical devices.